US 10,266,850

Application 13/842,859 · Granted Apr 23, 2019

Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

Estimated expiration

March 15, 2033

6y 116d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Mar 15, 2013
+ 20 years
Mar 15, 2033
PTA +78d
Jun 1, 2033
TD cap (US 10,000,772)
Mar 15, 2033
Final
Mar 15, 2033

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
March 15, 2013
Earliest effective filing
March 15, 2013
Issue date
April 23, 2019
PTA
+78 days
Base expiry (before PTA)
March 15, 2033

March 15, 2013 + 20 years = March 15, 2033 + 78 PTA days = June 1, 2033

  • PRO61/652,086 — Provisional — not used for base term
  • PRO61/716,256 — Provisional — not used for base term
  • PRO61/757,640 — Provisional — not used for base term
  • PRO61/765,576 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 3 filed

TD caps expiration to March 15, 2033 (earliest expiring referenced patent: US 10,000,772)

  • US 10,000,772· Application 14/685,502Capping patent

    Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

    Filing date
    Apr 13, 2015
    Earliest effective filing
    Mar 15, 2013
    Issue date
    Jun 19, 2018
    PTA
    0 days
    Calculated expiration
    Mar 15, 2033

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Mar 15, 2013 + 20y = Mar 15, 2033

  • US 10,113,167· Application 15/138,604

    Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

    Filing date
    Apr 26, 2016
    Earliest effective filing
    Mar 15, 2013
    Issue date
    Oct 30, 2018
    PTA
    0 days
    Calculated expiration
    Mar 15, 2033

    Continuation of 14/942,782, filed Nov 16, 2015, issued as US 10,227,611

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 14/685,516, filed Apr 13, 2015

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 14/685,514, filed Apr 13, 2015

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 14/685,513, filed Apr 13, 2015

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 14/685,504, filed Apr 13, 2015, issued as US 10,301,651

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 14/685,502, filed Apr 13, 2015, issued as US 10,000,772

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Mar 15, 2013 + 20y = Mar 15, 2033

  • US 10,301,651· Application 14/685,504(from application 14/685,504)

    Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

    Filing date
    Apr 13, 2015
    Earliest effective filing
    Mar 15, 2013
    Issue date
    May 28, 2019
    PTA
    0 days
    Calculated expiration
    Mar 15, 2033

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Mar 15, 2013 + 20y = Mar 15, 2033

  • US 10,227,611· Application 14/942,782(from application 14/942,782)

    Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

    Filing date
    Nov 16, 2015
    Earliest effective filing
    Mar 15, 2013
    Issue date
    Mar 12, 2019
    PTA
    0 days
    Calculated expiration
    Mar 15, 2033

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Mar 15, 2013 + 20y = Mar 15, 2033

  • US 10,407,697· Application 15/435,233(from application 15/435,233)

    Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

    Filing date
    Feb 16, 2017
    Earliest effective filing
    Mar 15, 2013
    Issue date
    Sep 10, 2019
    PTA
    0 days
    Calculated expiration
    Mar 15, 2033

    Continuation of 15/138,604, filed Apr 26, 2016, issued as US 10,113,167

    Continuation of 14/942,782, filed Nov 16, 2015, issued as US 10,227,611

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 14/685,516, filed Apr 13, 2015

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 14/685,514, filed Apr 13, 2015

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 14/685,513, filed Apr 13, 2015

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 14/685,504, filed Apr 13, 2015, issued as US 10,301,651

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 14/685,502, filed Apr 13, 2015, issued as US 10,000,772

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 14/942,782, filed Nov 16, 2015, issued as US 10,227,611

    Continuation of 13/842,859, filed Mar 15, 2013, issued as US 10,266,850

    Continuation of 14/685,516, filed Apr 13, 2015

    Continuation of 14/685,514, filed Apr 13, 2015

    Continuation of 14/685,513, filed Apr 13, 2015

    Continuation of 14/685,504, filed Apr 13, 2015, issued as US 10,301,651

    Continuation of 14/685,502, filed Apr 13, 2015, issued as US 10,000,772

    Mar 15, 2013 + 20y = Mar 15, 2033

Notes (1)

  • [TD_REFS_TRUNCATED] Found 34 TD references; resolving first 5 only

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 13/842,859 · US 10,266,850

PatentReply compiles the prosecution history behind US 10,266,850: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US10266850

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.